Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Pharmacology, Physiology, and Mechanisms of Action of Dipeptidyl Peptidase-4 Inhibitors
Erin E. Mulvihill, Daniel J. Drucker
Endocrine Reviews (2014) Vol. 35, Iss. 6, pp. 992-1019
Open Access | Times Cited: 528

Showing 51-75 of 528 citing articles:

The DPP-4 inhibitor vildagliptin impacts the gut microbiota and prevents disruption of intestinal homeostasis induced by a Western diet in mice
Marta Olivares, Audrey M. Neyrinck, Sarah A. Pötgens, et al.
Diabetologia (2018) Vol. 61, Iss. 8, pp. 1838-1848
Open Access | Times Cited: 85
In Silico Approaches to Identify Polyphenol Compounds as α-Glucosidase and α-Amylase Inhibitors against Type-II Diabetes
Jirawat Riyaphan, Dinh‐Chuong Pham, Max K. Leong, et al.
Biomolecules (2021) Vol. 11, Iss. 12, pp. 1877-1877
Open Access | Times Cited: 85
Diabetes and COVID-19; A Bidirectional Interplay
Paraskevi Kazakou, Vaia Lambadiari, Ignatios Ikonomidis, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 64
Evaluation of Biological Activity of Natural Compounds: Current Trends and Methods
Carlos Barba‐Ostria, Saskya E. Carrera-Pacheco, Rebeca González‐Pastor, et al.
Molecules (2022) Vol. 27, Iss. 14, pp. 4490-4490
Open Access | Times Cited: 64
Elucidating the Neuropathologic Mechanisms of SARS-CoV-2 Infection
Mar Pacheco‐Herrero, Luis O. Soto-Rojas, Charles R. Harrington, et al.
Frontiers in Neurology (2021) Vol. 12
Open Access | Times Cited: 60
Hyperglycemia in acute ischemic stroke: physiopathological and therapeutic complexity
RobertoFederico Villa, Federica Ferrari, Antonio Moretti
Neural Regeneration Research (2021) Vol. 17, Iss. 2, pp. 292-292
Open Access | Times Cited: 59
Peptide probes for proteases – innovations and applications for monitoring proteolytic activity
Maria Rodriguez-Rios, Alicia Megía-Fernández, Daniel J. Norman, et al.
Chemical Society Reviews (2022) Vol. 51, Iss. 6, pp. 2081-2120
Open Access | Times Cited: 55
Role of Dipeptidyl Peptidase 4 Inhibitors in Antidiabetic Treatment
Ruili Yin, Yongsong Xu, Xin Wang, et al.
Molecules (2022) Vol. 27, Iss. 10, pp. 3055-3055
Open Access | Times Cited: 50
Mechanisms of COVID-19 pathogenesis in diabetes
Chandrakala Aluganti Narasimhulu, Dinender K. Singla
AJP Heart and Circulatory Physiology (2022) Vol. 323, Iss. 3, pp. H403-H420
Open Access | Times Cited: 43
Computer-Aided Screening of Phytoconstituents from Ocimum tenuiflorum against Diabetes Mellitus Targeting DPP4 Inhibition: A Combination of Molecular Docking, Molecular Dynamics, and Pharmacokinetics Approaches
Harshit Sajal, Shashank M. Patil, Ranjith Raj, et al.
Molecules (2022) Vol. 27, Iss. 16, pp. 5133-5133
Open Access | Times Cited: 40
Evogliptin, a DPP-4 inhibitor, prevents diabetic cardiomyopathy by alleviating cardiac lipotoxicity in db/db mice
Trong Kha Pham, To Nguyen, Joo Mi Yi, et al.
Experimental & Molecular Medicine (2023) Vol. 55, Iss. 4, pp. 767-778
Open Access | Times Cited: 31
Comparison on cognitive outcomes of antidiabetic agents for type 2 diabetes: A systematic review and network meta‐analysis
Sai Tian, Jiaxuan Jiang, Jin Wang, et al.
Diabetes/Metabolism Research and Reviews (2023) Vol. 39, Iss. 7
Closed Access | Times Cited: 30
COVID-19: Diabetes Perspective—Pathophysiology and Management
Siva Dallavalasa, SubbaRao V. Tulimilli, Prakash Janhavi, et al.
Pathogens (2023) Vol. 12, Iss. 2, pp. 184-184
Open Access | Times Cited: 24
Risk of thyroid cancer associated with glucagon‐like peptide‐1 receptor agonists and dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes: A population‐based cohort study
Sungho Bea, Heejun Son, Jae Hyun Bae, et al.
Diabetes Obesity and Metabolism (2023) Vol. 26, Iss. 1, pp. 108-117
Closed Access | Times Cited: 24
Pharmacological Approaches Using Diabetic Drugs Repurposed for Alzheimer’s Disease
Muna A. Adem, Boris Decourt, Marwan N. Sabbagh
Biomedicines (2024) Vol. 12, Iss. 1, pp. 99-99
Open Access | Times Cited: 15
Cyclosporine-induced kidney damage was halted by sitagliptin and hesperidin via increasing Nrf2 and suppressing TNF-α, NF-κB, and Bax
Ahmed M. Abd-Eldayem, Sohayla Mahmoud Makram, Basim Anwar Shehata Messiha, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 13
DPP-4 inhibitors sitagliptin and PF-00734,200 mitigate dopaminergic neurodegeneration, neuroinflammation and behavioral impairment in the rat 6-OHDA model of Parkinson’s disease
Seong‐Jin Yu, Yun Wang, Hui Shen, et al.
GeroScience (2024) Vol. 46, Iss. 5, pp. 4349-4371
Open Access | Times Cited: 10
Guideline for the Management of Diabetes Mellitus in the Elderly in China (2024 Edition)
Lixin Guo, Xinhua Xiao
Aging Medicine (2024) Vol. 7, Iss. 1, pp. 5-51
Open Access | Times Cited: 9
Associations of antidiabetic drugs with diabetic retinopathy in people with type 2 diabetes: an umbrella review and meta-analysis
Luyuan Tan, Zhaonan Wang, Kelvin Okoth, et al.
Frontiers in Endocrinology (2024) Vol. 14
Open Access | Times Cited: 8
DPP4, a potential tumor biomarker, and tumor therapeutic target: review
Lu Sun, Yuhui Ma, Chenchen Geng, et al.
Molecular Biology Reports (2025) Vol. 52, Iss. 1
Closed Access | Times Cited: 1
Dipeptidyl Peptidase 4 Inhibition Stimulates Distal Tubular Natriuresis and Increases in Circulating SDF-1α1-67 in Patients With Type 2 Diabetes
Julie A. Lovshin, Harindra Rajasekeran, Yulyia Lytvyn, et al.
Diabetes Care (2017) Vol. 40, Iss. 8, pp. 1073-1081
Open Access | Times Cited: 86
Inhibition of Dipeptidyl Peptidase-4 Impairs Ventricular Function and Promotes Cardiac Fibrosis in High Fat–Fed Diabetic Mice
Erin E. Mulvihill, Elodie M. Varin, John R. Ussher, et al.
Diabetes (2015) Vol. 65, Iss. 3, pp. 742-754
Open Access | Times Cited: 81
A comparative study of the binding properties, dipeptidyl peptidase‐4 (DPP‐4) inhibitory activity and glucose‐lowering efficacy of the DPP‐4 inhibitors alogliptin, linagliptin, saxagliptin, sitagliptin and vildagliptin in mice
Joel P. Berger, Ranabir SinhaRoy, Alessandro Pocai, et al.
Endocrinology Diabetes & Metabolism (2017) Vol. 1, Iss. 1
Open Access | Times Cited: 79
Dipeptidyl Peptidase-4 Regulation of SDF-1/CXCR4 Axis: Implications for Cardiovascular Disease
Jixin Zhong, Sanjay Rajagopalan
Frontiers in Immunology (2015) Vol. 6
Open Access | Times Cited: 72
Gut-brain connection: The neuroprotective effects of the anti-diabetic drug liraglutide
Emanuel Candeias
World Journal of Diabetes (2015) Vol. 6, Iss. 6, pp. 807-807
Open Access | Times Cited: 71

Scroll to top